Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 44 articles: HTML format

Single Articles

September 2025
1. NOUREDDIN M, Shringarpure R, Yale K
   Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. Reply.
   N Engl J Med. 2025;393:10.
   PubMed    
   
   
   
2. YU L
   Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
   N Engl J Med. 2025;393:10.
   PubMed    
   
   
   August 2025
3. SANYAL AJ, Newsome PN
   Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. Reply.
   N Engl J Med. 2025;393:827-828.
   PubMed    
   
   
   
4. SU CY, Hasebe M
   Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
   N Engl J Med. 2025;393:827.
   PubMed    
   
   
   
5. RIVERA-ESTEBAN J, Valverde-Salazar V, Calleja JL
   Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
   N Engl J Med. 2025;393:827.
   PubMed    
   
   
   
6. LAVENDER J, Bollipo S, Talley N
   Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
   N Engl J Med. 2025;393:826.
   PubMed    
   
   
   
7. LUO S, Liu H, Jin W
   Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
   N Engl J Med. 2025;393:826.
   PubMed    
   
   
   June 2025
8. GARCIA-TSAO G
   Redefining End Points in MASH Cirrhosis.
   N Engl J Med. 2025;392:2475-2477.
   PubMed    
   
   
   
9. SIMON TG
   Semaglutide for Metabolic Dysfunction-Associated Steatohepatitis.
   N Engl J Med. 2025;392:2160-2161.
   PubMed    
   
   
   May 2025
10. NOUREDDIN M, Rinella ME, Chalasani NP, Neff GW, et al
    Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
    N Engl J Med. 2025 May 9. doi: 10.1056/NEJMoa2502242.
    PubMed     Abstract available
    
    
    
11. MARTIN L, Maric D, Idriss S, Delamare M, et al
    Identification of Hepatic-like EPO as a Cause of Polycythemia.
    N Engl J Med. 2025;392:1684-1697.
    PubMed     Abstract available
    
    
    April 2025
12. SANYAL AJ, Newsome PN, Kliers I, Ostergaard LH, et al
    Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2025 Apr 30. doi: 10.1056/NEJMoa2413258.
    PubMed     Abstract available
    
    
    
13. RASKO JEJ, Samelson-Jones BJ, George LA, Giermasz A, et al
    Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.
    N Engl J Med. 2025;392:1508-1517.
    PubMed     Abstract available
    
    
    March 2025
14. COREY KE, Dudzinski DM, Guimaraes AR, Mino-Kenudson M, et al
    Case 9-2025: A 59-Year-Old Man with Hepatocellular Carcinoma.
    N Engl J Med. 2025;392:1216-1227.
    PubMed    
    
    
    October 2024
15. SJOHOLM A, Mahma H
    Glycogenic Hepatopathy.
    N Engl J Med. 2024;391:1528.
    PubMed    
    
    
    
16. MEI Z, Pu J, Shao Z
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461-1462.
    PubMed    
    
    
    
17. POLYZOS SA
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461.
    PubMed    
    
    
    September 2024
18. COHEN PA, Broad Leib EM
    Ingesting Risk - The FDA and New Food Ingredients.
    N Engl J Med. 2024;391:875-877.
    PubMed    
    
    
    August 2024
19. HERNANDEZ PEREZ JM
    Alpha(1)-Antitrypsin Deficiency.
    N Engl J Med. 2024;391:e16.
    PubMed    
    
    
    July 2024
20. KANWAL F
    Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2024;391:371-372.
    PubMed    
    
    
    
21. SANYAL AJ, Bedossa P, Fraessdorf M, Neff GW, et al
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
    N Engl J Med. 2024;391:311-319.
    PubMed     Abstract available
    
    
    
22. SCHUBACH A, Carr RM, Abdelmalek MF
    Hepatologist Consultation in Low-Risk MASLD.
    N Engl J Med. 2024;391:373-375.
    PubMed    
    
    
    June 2024
23. GANAPATHI L, Cochran RL, Robbins GK, Barmettler S, et al
    Case 20-2024: A 73-Year-Old Man with Recurrent Fever and Liver Lesions.
    N Engl J Med. 2024;390:2309-2319.
    PubMed    
    
    
    
24. LOOMBA R, Hartman ML, Lawitz EJ, Vuppalanchi R, et al
    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    N Engl J Med. 2024 Jun 8. doi: 10.1056/NEJMoa2401943.
    PubMed     Abstract available
    
    
    May 2024
25. KOWDLEY KV, Levy C, Jones D
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1935-1936.
    PubMed    
    
    
    
26. HIRSCHFIELD GM, Kremer AE, Levy C
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1934-1935.
    PubMed    
    
    
    
27. IJICHI H
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1934.
    PubMed    
    
    
    
28. AREVALO-CANAS C, Arevalo-Serrano J
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1933-1934.
    PubMed    
    
    
    
29. NAJEM M, Dong E
    Esophageal Varices, White-Nipple Sign, and Portal Hypertensive Gastropathy.
    N Engl J Med. 2024;390:e47.
    PubMed    
    
    
    
30. HARRISON SA, Taub R
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
    N Engl J Med. 2024;390:1632-1633.
    PubMed    
    
    
    
31. SABET A
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:1632.
    PubMed    
    
    
    February 2024
32. SCHNABL B
    PPAR Agonists in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:855-858.
    PubMed    
    
    
    
33. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:783-794.
    PubMed     Abstract available
    
    
    
34. ASSIS DN
    Advancing Second-Line Treatment for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:853-854.
    PubMed    
    
    
    
35. CUSI K
    Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
    N Engl J Med. 2024;390:559-561.
    PubMed    
    
    
    
36. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    PubMed     Abstract available
    
    
    December 2023
37. CAI S, Kuang M
    Clonorchis sinensis Liver Flukes.
    N Engl J Med. 2023;389:e57.
    PubMed    
    
    
    
38. LOOMBA R, Mansbach H, Margalit M
    Randomized Trial of Pegozafermin in NASH. Reply.
    N Engl J Med. 2023;389:2210.
    PubMed    
    
    
    
39. PATOULIAS D
    Randomized Trial of Pegozafermin in NASH.
    N Engl J Med. 2023;389:2209-2210.
    PubMed    
    
    
    November 2023
40. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    PubMed     Abstract available
    
    
    
41. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed     Abstract available
    
    
    September 2023
42. RINELLA ME
    Pegozafermin for NASH - A Sprint to Start a Marathon.
    N Engl J Med. 2023;389:1044-1046.
    PubMed    
    
    
    
43. LOOMBA R, Sanyal AJ, Kowdley KV, Bhatt DL, et al
    Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
    N Engl J Med. 2023;389:998-1008.
    PubMed     Abstract available
    
    
    
44. ROBERTS EA, Schilsky ML
    Current and Emerging Issues in Wilson's Disease.
    N Engl J Med. 2023;389:922-938.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.